First Tracks Biotherapeutics

First Tracks Biotherapeutics is a Boston-based biotechnology company focused on the discovery and development of novel small molecule therapies for cancer and immunological diseases. Founded in 2022 by serial entrepreneur Gary Glick, the company leverages a proprietary discovery platform to target high-value biological pathways that have been difficult to drug with traditional methods. The firm operates primarily in stealth mode, building a pipeline of pre-clinical programs aimed at addressing significant unmet needs in oncology. Backed by top-tier life science venture capital firms, First Tracks combines deep expertise in medicinal chemistry with advanced biological insights. The company's mission is to create transformative medicines that provide new options for patients with hard-to-treat malignancies.